Active, not recruitingPhase 3NCT04210115
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- pembrolizumab(biological)
- Enrollment
- 703 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691), Long Beach, California, United States
- Columbus Regional Research Institute ( Site 0047), Columbus, Georgia, United States
- University of Kansas Cancer Center ( Site 0023), Westwood, Kansas, United States
- Cancer Center of Kansas ( Site 0058), Wichita, Kansas, United States
- University Medical Center ( Site 0035), New Orleans, Louisiana, United States
- Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, United States
- Dana Farber Cancer Center ( Site 0034), Boston, Massachusetts, United States
- Henry Ford Hospital ( Site 0685), Detroit, Michigan, United States
- University of Missouri ( Site 0688), Columbia, Missouri, United States
- Renown Regional Medical Center ( Site 0706), Reno, Nevada, United States
- Rutgers Cancer Institute of New Jersey ( Site 0695), New Brunswick, New Jersey, United States
- Weill Cornell Medical College ( Site 0053), New York, New York, United States
- Stephenson Cancer Center ( Site 0044), Oklahoma City, Oklahoma, United States
- Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060), Portland, Oregon, United States
- Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04210115 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →